The recent 5% dip in NVIDIA (NVDA) is a prime buying opportunity, as the stock remains one of the cheapest high-growth plays in the Magnificent 7 ahead of the upcoming GTC conference and Ruben product launch. Zeta Global (ZETA) offers a high-conviction entry into AI-driven marketing, trading at a significant valuation discount despite guidance for 35% revenue growth through 2026. In the Buy Now, Pay Later sector, Sezzle (SEZL) continues to outperform traditional credit models, though investors may find better value in Klarna following its recent drawdown. Avoid "catching the falling knife" with Oddity Tech (ODD), as its growth thesis has collapsed; look to Hims & Hers (HIMS) for a more stable alternative in the direct-to-consumer space. For healthcare exposure, maintain a cautious Hold on TransMedix Group (TMDX), as slowing growth and long-term disruption from United Therapeutics (UTHR) limit its immediate upside.

NVIDIA (NVDA)

• The stock dropped 5% despite a "stellar" Q4 beat and raise, which the analyst describes as "entirely nonsensical" and driven by traders rather than fundamentals.
• Key Metrics: Currently the second cheapest stock in the "Magnificent 7" (after Meta) when factoring in growth. If revenue growth hits 60% in 2026, it may become the cheapest.
• Sector Dynamics: Demand is so high that the company is deprioritizing the gaming sector to divert chips toward AI.
• Capital Allocation: Management is choosing to invest in an "equity stake conglomerate" of AI startups rather than aggressive buybacks, despite having $60 billion in cash, because they see better returns in the ecosystem.
• Future Catalysts: Upcoming GTC conference and the next-generation product line, Ruben.

Takeaways

• Bullish Sentiment: The analyst views the current price dip as a disconnect from reality, noting the stock is technically "cheaper than Walmart" on an EV/Gross Profit basis.
• Investment Insight: Look past the short-term liquidity issues and trader-driven volatility; the fundamental "moat" is expanding through strategic investments in other AI companies.

Zeta Global (ZETA)

• The stock rose 16% following strong earnings and is being labeled by some as the "Palantir of Marketing."
• Valuation: Trading at an Enterprise Value/Gross Profit (EV/GP) of 0.15, which is considered "dirt cheap" for a software company.
• Guidance: Management provided high visibility with 34-35% revenue growth guidance for 2026 and a long-term 2028 revenue target of $2.3 billion.
• Product: Their AI agent, Athena, is driving a narrative shift that could lead to a valuation re-rating similar to other high-growth AI stocks.

Takeaways

• Actionable Insight: Zeta offers a high "Rule of 40" score (56) at a fraction of the valuation of peers like Palantir.
• Growth Potential: The transition from $1.3B to $2.3B in revenue by 2028 suggests a sustained growth trajectory.

Sezzle (SEZL)

• The stock surged 35% following earnings, continuing a "mega-trend" in the Buy Now, Pay Later (BNPL) space favored by Gen Z.
• Comparison: The analyst views Sezzle as a "no-brainer" compared to Affirm (AFRM). While it grows at a similar rate to Klarna, Sezzle is more profitable but currently three times more expensive.
• Performance: Described as "firing on all cylinders" and successfully replacing traditional credit card models with better credit decisioning.

Takeaways

• Sentiment: Bullish but cautious on entry price after the recent 35% run.
• Preference: The analyst slightly prefers Klarna at current levels due to its 70% drawdown from IPO highs, but maintains that Sezzle's thesis is not broken.

Oddity Tech (ODD)

• Described as a "brutal disaster" and a "broken thesis" after the stock dropped roughly 45-55% in a matter of days.
• The Issue: The company swung from a long-term guidance of 20% growth to -30% growth.
• Root Cause: Allegedly placed in a "penalty box" by Meta/TikTok regarding their "try before you buy" ads, causing customer acquisition costs to skyrocket.
• Valuation: While the P/E ratio (6) and EV/EBITDA (7) look attractive to value investors, the analyst is exiting because the growth story has vanished.

Takeaways

• Bearish Sentiment: The stock is expected to be "dead money" until at least 2027.
• Risk Factor: High dependency on social media advertising algorithms; if the "ad engine" breaks, the growth model fails.
• Actionable Insight: Avoid "catching the falling knife" here; the analyst prefers Hims & Hers (HIMS) as a more stable alternative in the Direct-to-Consumer (DTC) space.

TransMedix Group (TMDX)

• The company is executing well, but the analyst is becoming a "growth snob," noting that 20-25% guidance is lower than the preferred 30%+.
• Risks: Healthcare stocks face "single decision-maker" risks (FDA, insurance reimbursement changes).
• Competition: Long-term threat from Xenografts (pig-grown organs), with companies like United Therapeutics (UTHR) investing heavily in this disruptive tech.

Takeaways

• Investment Stance: Hold. The stock is perceived as "a little pricey" at current levels.
• Timeline: Viewed as a medium-term hold rather than a long-term "forever" stock due to eventual disruption in the organ transplant market.

Investment Themes & Sectors

• The "SaaS-pocalypse": Many high-growth software and innovative stocks (e.g., ServiceNow, Duolingo, Enphase) have seen 50-70% drawdowns, creating a "brutal" environment for innovation investors.
• BNPL vs. Credit: A structural shift is occurring where Gen Z is moving away from traditional credit cards toward BNPL platforms that use real-time credit decisioning.
• Market Dysfunction: The analyst repeatedly notes that the market is currently "broken," failing to reward companies (like NVIDIA) for fundamental outperformance.